Mesobiliverdin IXα enhances rat pancreatic islet yield and function

Taihei Ito, Dong Chen, Cheng Wei Tom Chang, Takashi Kenmochi, Tomonori Saito, Satoshi Suzuki, Jon Y. Takemoto

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The aims of this study were to produce mesobiliverdin IXα, an analog of anti-inflammatory biliverdin IXα, and to test its ability to enhance rat pancreatic islet yield for allograft transplantation into diabetic recipients. Mesobiliverdin IXα was synthesized from phycocyanobilin derived from cyanobacteria, and its identity and purity were analyzed by chromatographic and spectroscopic methods. Mesobiliverdin IXα was a substrate for human NADPH biliverdin reductase. Excised Lewis rat pancreata infused with mesobiliverdin IXα and biliverdin IXα-HCl (1-100 μM) yielded islet equivalents as high as 86.7 and 36.5%, respectively, above those from non-treated controls, and the islets showed a high degree of viability based on dithizone staining. When transplanted into livers of streptozotocin-induced diabetic rats, islets from pancreata infused with mesobiliverdin IXα lowered non-fasting blood glucose (BG) levels in 55.6% of the recipients and in 22.2% of control recipients. In intravenous glucose tolerance tests, fasting BG levels of 56 post-operative day recipients with islets from mesobiliverdin IXα infused pancreata were lower than those for controls and showed responses that indicate recovery of insulin-dependent function. In conclusion, mesobiliverdin IXα infusion of pancreata enhanced yields of functional islets capable of reversing insulin dysfunction in diabetic recipients. Since its production is scalable, mesobiliverdin IXα has clinical potential as a protectant of pancreatic islets for allograft transplantation.

Original languageEnglish
Article numberArticle 50
JournalFrontiers in Pharmacology
Volume4 APR
DOIs
Publication statusPublished - 20-08-2013

Fingerprint

Islets of Langerhans
Pancreas
Biliverdine
biliverdin reductase
Allografts
Blood Glucose
Dithizone
Insulin
Islets of Langerhans Transplantation
Aptitude
mesobiliverdin
Cyanobacteria
Glucose Tolerance Test
Streptozocin
NADP
Fasting
Anti-Inflammatory Agents
Transplantation
Staining and Labeling
Liver

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Ito, T., Chen, D., Chang, C. W. T., Kenmochi, T., Saito, T., Suzuki, S., & Takemoto, J. Y. (2013). Mesobiliverdin IXα enhances rat pancreatic islet yield and function. Frontiers in Pharmacology, 4 APR, [Article 50]. https://doi.org/10.3389/fphar.2013.00050
Ito, Taihei ; Chen, Dong ; Chang, Cheng Wei Tom ; Kenmochi, Takashi ; Saito, Tomonori ; Suzuki, Satoshi ; Takemoto, Jon Y. / Mesobiliverdin IXα enhances rat pancreatic islet yield and function. In: Frontiers in Pharmacology. 2013 ; Vol. 4 APR.
@article{65fbe686bc98438bb199eae18534249c,
title = "Mesobiliverdin IXα enhances rat pancreatic islet yield and function",
abstract = "The aims of this study were to produce mesobiliverdin IXα, an analog of anti-inflammatory biliverdin IXα, and to test its ability to enhance rat pancreatic islet yield for allograft transplantation into diabetic recipients. Mesobiliverdin IXα was synthesized from phycocyanobilin derived from cyanobacteria, and its identity and purity were analyzed by chromatographic and spectroscopic methods. Mesobiliverdin IXα was a substrate for human NADPH biliverdin reductase. Excised Lewis rat pancreata infused with mesobiliverdin IXα and biliverdin IXα-HCl (1-100 μM) yielded islet equivalents as high as 86.7 and 36.5{\%}, respectively, above those from non-treated controls, and the islets showed a high degree of viability based on dithizone staining. When transplanted into livers of streptozotocin-induced diabetic rats, islets from pancreata infused with mesobiliverdin IXα lowered non-fasting blood glucose (BG) levels in 55.6{\%} of the recipients and in 22.2{\%} of control recipients. In intravenous glucose tolerance tests, fasting BG levels of 56 post-operative day recipients with islets from mesobiliverdin IXα infused pancreata were lower than those for controls and showed responses that indicate recovery of insulin-dependent function. In conclusion, mesobiliverdin IXα infusion of pancreata enhanced yields of functional islets capable of reversing insulin dysfunction in diabetic recipients. Since its production is scalable, mesobiliverdin IXα has clinical potential as a protectant of pancreatic islets for allograft transplantation.",
author = "Taihei Ito and Dong Chen and Chang, {Cheng Wei Tom} and Takashi Kenmochi and Tomonori Saito and Satoshi Suzuki and Takemoto, {Jon Y.}",
year = "2013",
month = "8",
day = "20",
doi = "10.3389/fphar.2013.00050",
language = "English",
volume = "4 APR",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",

}

Mesobiliverdin IXα enhances rat pancreatic islet yield and function. / Ito, Taihei; Chen, Dong; Chang, Cheng Wei Tom; Kenmochi, Takashi; Saito, Tomonori; Suzuki, Satoshi; Takemoto, Jon Y.

In: Frontiers in Pharmacology, Vol. 4 APR, Article 50, 20.08.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mesobiliverdin IXα enhances rat pancreatic islet yield and function

AU - Ito, Taihei

AU - Chen, Dong

AU - Chang, Cheng Wei Tom

AU - Kenmochi, Takashi

AU - Saito, Tomonori

AU - Suzuki, Satoshi

AU - Takemoto, Jon Y.

PY - 2013/8/20

Y1 - 2013/8/20

N2 - The aims of this study were to produce mesobiliverdin IXα, an analog of anti-inflammatory biliverdin IXα, and to test its ability to enhance rat pancreatic islet yield for allograft transplantation into diabetic recipients. Mesobiliverdin IXα was synthesized from phycocyanobilin derived from cyanobacteria, and its identity and purity were analyzed by chromatographic and spectroscopic methods. Mesobiliverdin IXα was a substrate for human NADPH biliverdin reductase. Excised Lewis rat pancreata infused with mesobiliverdin IXα and biliverdin IXα-HCl (1-100 μM) yielded islet equivalents as high as 86.7 and 36.5%, respectively, above those from non-treated controls, and the islets showed a high degree of viability based on dithizone staining. When transplanted into livers of streptozotocin-induced diabetic rats, islets from pancreata infused with mesobiliverdin IXα lowered non-fasting blood glucose (BG) levels in 55.6% of the recipients and in 22.2% of control recipients. In intravenous glucose tolerance tests, fasting BG levels of 56 post-operative day recipients with islets from mesobiliverdin IXα infused pancreata were lower than those for controls and showed responses that indicate recovery of insulin-dependent function. In conclusion, mesobiliverdin IXα infusion of pancreata enhanced yields of functional islets capable of reversing insulin dysfunction in diabetic recipients. Since its production is scalable, mesobiliverdin IXα has clinical potential as a protectant of pancreatic islets for allograft transplantation.

AB - The aims of this study were to produce mesobiliverdin IXα, an analog of anti-inflammatory biliverdin IXα, and to test its ability to enhance rat pancreatic islet yield for allograft transplantation into diabetic recipients. Mesobiliverdin IXα was synthesized from phycocyanobilin derived from cyanobacteria, and its identity and purity were analyzed by chromatographic and spectroscopic methods. Mesobiliverdin IXα was a substrate for human NADPH biliverdin reductase. Excised Lewis rat pancreata infused with mesobiliverdin IXα and biliverdin IXα-HCl (1-100 μM) yielded islet equivalents as high as 86.7 and 36.5%, respectively, above those from non-treated controls, and the islets showed a high degree of viability based on dithizone staining. When transplanted into livers of streptozotocin-induced diabetic rats, islets from pancreata infused with mesobiliverdin IXα lowered non-fasting blood glucose (BG) levels in 55.6% of the recipients and in 22.2% of control recipients. In intravenous glucose tolerance tests, fasting BG levels of 56 post-operative day recipients with islets from mesobiliverdin IXα infused pancreata were lower than those for controls and showed responses that indicate recovery of insulin-dependent function. In conclusion, mesobiliverdin IXα infusion of pancreata enhanced yields of functional islets capable of reversing insulin dysfunction in diabetic recipients. Since its production is scalable, mesobiliverdin IXα has clinical potential as a protectant of pancreatic islets for allograft transplantation.

UR - http://www.scopus.com/inward/record.url?scp=84881516515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881516515&partnerID=8YFLogxK

U2 - 10.3389/fphar.2013.00050

DO - 10.3389/fphar.2013.00050

M3 - Article

C2 - 23630498

AN - SCOPUS:84881516515

VL - 4 APR

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - Article 50

ER -